Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges

被引:8
作者
Kim, Dana [1 ,2 ]
Kim, Young-Sam [3 ]
Shin, Dong Wun [4 ]
Park, Chang-Shin [1 ,2 ]
Kang, Ju-Hee [1 ]
机构
[1] Res Ctr, Dept Pharmacol & Med Toxicol, Inchon, South Korea
[2] Inha Univ, Hypoxia Related Dis Res Ctr, Sch Med, Inchon, South Korea
[3] Inha Univ, Inha Univ Hosp, Dept Thorac Surg, Inchon, South Korea
[4] Inje Univ, Dept Emergency Med, Ilsan Paik Hosp, Goyang, South Korea
来源
JOURNAL OF CLINICAL NEUROLOGY | 2016年 / 12卷 / 04期
基金
新加坡国家研究基金会;
关键词
cerebrospinal fluid; Alzheimer's disease; Parkinson's disease; biomarker; clinical trial; disease-modifying therapy; GAMMA-SECRETASE INHIBITOR; MILD COGNITIVE IMPAIRMENT; BETA-AMYLOID; 1-42; ALPHA-SYNUCLEIN; DOUBLE-BLIND; CSF BIOMARKERS; TAU PROTEINS; DEMENTIA; SAFETY; DIAGNOSIS;
D O I
10.3988/jcn.2016.12.4.381
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
No disease-modifying therapies (DMT) for neurodegenerative diseases (NDs) have been established, particularly for Alzheimer's disease (AD) and Parkinson's disease (PD). It is unclear why candidate drugs that successfully demonstrate therapeutic effects in animal models fail to show disease-modifying effects in clinical trials. To overcome this hurdle, patients with homogeneous pathologies should be detected as early as possible. The early detection of AD patients using sufficiently tested biomarkers could demonstrate the potential usefulness of combining biomarkers with clinical measures as a diagnostic tool. Cerebrospinal fluid (CSF) biomarkers for NDs are being incorporated in clinical trials designed with the aim of detecting patients earlier, evaluating target engagement, collecting homogeneous patients, facilitating prevention trials, and testing the potential of surrogate markers relative to clinical measures. In this review we summarize the latest information on CSF biomarkers in NDs, particularly AD and PD, and their use in clinical trials. The large number of issues related to CSF biomarker measurements and applications has resulted in relatively few clinical trials on CSF biomarkers being conducted. However, the available CSF biomarker data obtained in clinical trials support the advantages of incorporating CSF biomarkers in clinical trials, even though the data have mostly been obtained in AD trials. We describe the current issues with and ongoing efforts for the use of CSF biomarkers in clinical trials and the plans to harness CSF biomarkers for the development of DMT and clinical routines. This effort requires nationwide, global, and multidisciplinary efforts in academia, industry, and regulatory agencies to facilitate a new era.
引用
收藏
页码:381 / 392
页数:12
相关论文
共 82 条
  • [1] AZD3293 A NOVEL BACE1 INHIBITOR: SAFETY, TOLERABILITY, AND EFFECTS ON PLASMA AND CSF Aβ PEPTIDES FOLLOWING SINGLE- AND MULTIPLE-DOSE ADMINISTRATION
    Alexander, Robert
    Budd, S.
    Russell, M.
    Kugler, A.
    Cebers, G.
    Ye, N.
    Olsson, T.
    Burdette, D.
    Maltby, J.
    Paraskos, J.
    Elsby, K.
    Han, D.
    Goldwater, R.
    Ereshefsky, L.
    [J]. NEUROBIOLOGY OF AGING, 2014, 35 : S2 - S2
  • [2] CSF Aβ42 predicts early-onset dementia in Parkinson disease
    Alves, Guido
    Lange, Johannes
    Blennow, Kaj
    Zetterberg, Henrik
    Andreasson, Ulf
    Forland, Marthe G.
    Tysnes, Ole-Bjorn
    Larsen, Jan P.
    Pedersen, Kenn F.
    [J]. NEUROLOGY, 2014, 82 (20) : 1784 - 1790
  • [3] First Administration of the Fc-Attenuated Anti-β Amyloid Antibody GSK933776 to Patients with Mild Alzheimer's Disease: A Randomized, Placebo-Controlled Study
    Andreasen, Niels
    Simeoni, Monica
    Ostlund, Henrik
    Lisjo, Pia I.
    Fladby, Tormod
    Loercher, Amy E.
    Byrne, Gerard J.
    Murray, Frances
    Scott-Stevens, Paul T.
    Wallin, Anders
    Zhang, Yinghua Y.
    Bronge, Lena H.
    Zetterberg, Henrik
    Nordberg, Agneta K.
    Yeo, Astrid J.
    Khan, Shahid A.
    Hilpert, Jan
    Mistry, Prafull C.
    [J]. PLOS ONE, 2015, 10 (03):
  • [4] [Anonymous], 2012, ALZHEIMERS DEMENT
  • [5] Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
    Atkinson, AJ
    Colburn, WA
    DeGruttola, VG
    DeMets, DL
    Downing, GJ
    Hoth, DF
    Oates, JA
    Peck, CC
    Schooley, RT
    Spilker, BA
    Woodcock, J
    Zeger, SL
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) : 89 - 95
  • [6] The Alzheimer's Prevention Initiative Composite Cognitive Test Score: Sample Size Estimates for the Evaluation of Preclinical Alzheimer's Disease Treatments in Presenilin 1 E280A Mutation Carriers
    Ayutyanont, Napatkamon
    Langbaum, Jessica B. S.
    Hendrix, Suzanne B.
    Chen, Kewei
    Fleisher, Adam S.
    Friesenhahn, Michel
    Ward, Michael
    Aguirre, Camilo
    Acosta-Baena, Natalia
    Madrigal, Lucia
    Munoz, Claudia
    Tirado, Victoria
    Moreno, Sonia
    Tariot, Pierre N.
    Lopera, Francisco
    Reiman, Eric M.
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2014, 75 (06) : 652 - 660
  • [7] Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
    Bateman, Randall J.
    Xiong, Chengjie
    Benzinger, Tammie L. S.
    Fagan, Anne M.
    Goate, Alison
    Fox, Nick C.
    Marcus, Daniel S.
    Cairns, Nigel J.
    Xie, Xianyun
    Blazey, Tyler M.
    Holtzman, David M.
    Santacruz, Anna
    Buckles, Virginia
    Oliver, Angela
    Moulder, Krista
    Aisen, Paul S.
    Ghetti, Bernardino
    Klunk, William E.
    McDade, Eric
    Martins, Ralph N.
    Masters, Colin L.
    Mayeux, Richard
    Ringman, John M.
    Rossor, Martin N.
    Schofield, Peter R.
    Sperling, Reisa A.
    Salloway, Stephen
    Morris, John C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (09) : 795 - 804
  • [8] Bell J, 2013, ALZHEIMERS DEMENT S, V9, P287, DOI http://dx.doi.org/10.1016/j.jalz.2013.05.578
  • [9] Bernier F, 2013, ALZHEIMERS DEMENT, V9, pP886, DOI DOI 10.1016/J.JALZ.2013.08.244
  • [10] Presymptomatic compensation in Parkinson's disease is not dopamine-mediated
    Bezard, E
    Gross, CE
    Brotchie, JM
    [J]. TRENDS IN NEUROSCIENCES, 2003, 26 (04) : 215 - 221